Physician profile
Marilyn Jackson
NPI 1699847913
$445.69
in general payments reported to CMS, 2019-2025
13 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $14.70 · 2023: $90.69 · 2024: $120 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $93.14 | 2023-2025 | Nexplanon |
| Abbott Laboratories | $67.11 | 2024-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $46.07 | 2023-2024 | Wegovy |
| Abbvie INC. | $40.29 | 2021 | |
| Pfizer INC. | $36.12 | 2023 | |
| Evofem Biosciences, INC. | $30.78 | 2021 | |
| Cranial Technologies, INC | $28.98 | 2021-2022 | |
| Glaxosmithkline, LLC. | $24.21 | 2025 | Shingrix |
| Coopersurgical, INC. | $23.38 | 2024 | Paragard T 380a |
| Dexcom, INC. | $17.62 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $14.48 | 2023 | Myfembree |
| Merck Sharp & Dohme LLC | $12.38 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.